Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV

Davor Skaricic, Chani Traube, Bishnu De, Ju Joh, Julie Boyer, Ronald Crystal, Stefan Worgall

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Respiratory syncytial virus (RSV) is a common cause of severe lower respiratory tract infections. Protection against infection with RSV can be achieved by monthly administration of the humanized monoclonal antibody palivizumab. The present study analyzes if genetic delivery of a murine version of palivizumab by single administration would achieve high-level and sustained antibody expression to protect mice against pulmonary infection with RSV. A murine version of the palivizumab antibody was constructed by replacing the human sequences with sequences from the constant region of a murine IgG1 antibody, while preserving the complementarity-determining region. As a proof-of-principle to test the validity of the strategy, the coding sequence for the heavy and light chains were cloned into a replication-defective serotype 5 human adenovirus vector (AdαRSV). Antibody expression and specificity for RSV was confirmed by Western analysis. To determine if AdαRSV would mediate production of anti-RSV antibodies in vivo, 5 × 1010 particle units of AdαRSV or a control vector without transgene (AdNull), were administered intravenously to BALB/c mice. RSV neutralizing antibodies were detected in the serum after 4 days in mice receiving AdαRSV but not in AdNull-infected or naive mice (p < 0.05). The mice that had received AdαRSV had at least 5.4-fold lower RSV titers in the lung 4 days following intranasal challenge with RSV compared to the AdNull or naive group (p < 0.01). To evaluate long-term protection, the antibody construct was expressed in a non-human primate serotype rh.10 adeno-associated virus vector (AAVrh.10αRSV). RSV neutralizing antibodies were detected in serum and bronchoalveolar lavage fluid for up to 21 wk following intrapleural administration of AAVrh.10αRSV, but not with a control AAV vector expressing an unrelated transgene (AAVrh.10α1AT). Following challenge with RSV at 7 or 21 wk, 14.3-fold and 10.6-fold lower RSV titers were observed after 4 days in the lungs of mice that had received AAVrh.10αRSV compared to AAVrh.10α1AT (p < 0.05). Together these data demonstrate that a gene transfer strategy for delivery of an anti-RSV antibody can generate protective immunity in mice against RSV infection in the respiratory tract and may provide an alternative to the administration of the antibody itself.

Original languageEnglish
Pages (from-to)79-85
Number of pages7
JournalVirology
Volume378
Issue number1
DOIs
Publication statusPublished - 15 Aug 2008
Externally publishedYes

Fingerprint

Respiratory Syncytial Virus Infections
Respiratory Syncytial Viruses
Lung
Antibodies
Adenoviridae
Neutralizing Antibodies
Viral Load
Transgenes
Complementarity Determining Regions
Antibodies, Monoclonal, Humanized
Human Adenoviruses
Dependovirus
Antibody Specificity
Bronchoalveolar Lavage Fluid
Serum
Respiratory Tract Infections
Respiratory System
Primates
Immunity

Keywords

  • Antibody
  • RSV
  • RSVAntibody">Gene therapy vectors

ASJC Scopus subject areas

  • Virology

Cite this

Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV. / Skaricic, Davor; Traube, Chani; De, Bishnu; Joh, Ju; Boyer, Julie; Crystal, Ronald; Worgall, Stefan.

In: Virology, Vol. 378, No. 1, 15.08.2008, p. 79-85.

Research output: Contribution to journalArticle

Skaricic, D, Traube, C, De, B, Joh, J, Boyer, J, Crystal, R & Worgall, S 2008, 'Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV', Virology, vol. 378, no. 1, pp. 79-85. https://doi.org/10.1016/j.virol.2008.04.016
Skaricic, Davor ; Traube, Chani ; De, Bishnu ; Joh, Ju ; Boyer, Julie ; Crystal, Ronald ; Worgall, Stefan. / Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV. In: Virology. 2008 ; Vol. 378, No. 1. pp. 79-85.
@article{a3e16c8aba414931b814c7c4e27612ec,
title = "Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV",
abstract = "Respiratory syncytial virus (RSV) is a common cause of severe lower respiratory tract infections. Protection against infection with RSV can be achieved by monthly administration of the humanized monoclonal antibody palivizumab. The present study analyzes if genetic delivery of a murine version of palivizumab by single administration would achieve high-level and sustained antibody expression to protect mice against pulmonary infection with RSV. A murine version of the palivizumab antibody was constructed by replacing the human sequences with sequences from the constant region of a murine IgG1 antibody, while preserving the complementarity-determining region. As a proof-of-principle to test the validity of the strategy, the coding sequence for the heavy and light chains were cloned into a replication-defective serotype 5 human adenovirus vector (AdαRSV). Antibody expression and specificity for RSV was confirmed by Western analysis. To determine if AdαRSV would mediate production of anti-RSV antibodies in vivo, 5 × 1010 particle units of AdαRSV or a control vector without transgene (AdNull), were administered intravenously to BALB/c mice. RSV neutralizing antibodies were detected in the serum after 4 days in mice receiving AdαRSV but not in AdNull-infected or naive mice (p < 0.05). The mice that had received AdαRSV had at least 5.4-fold lower RSV titers in the lung 4 days following intranasal challenge with RSV compared to the AdNull or naive group (p < 0.01). To evaluate long-term protection, the antibody construct was expressed in a non-human primate serotype rh.10 adeno-associated virus vector (AAVrh.10αRSV). RSV neutralizing antibodies were detected in serum and bronchoalveolar lavage fluid for up to 21 wk following intrapleural administration of AAVrh.10αRSV, but not with a control AAV vector expressing an unrelated transgene (AAVrh.10α1AT). Following challenge with RSV at 7 or 21 wk, 14.3-fold and 10.6-fold lower RSV titers were observed after 4 days in the lungs of mice that had received AAVrh.10αRSV compared to AAVrh.10α1AT (p < 0.05). Together these data demonstrate that a gene transfer strategy for delivery of an anti-RSV antibody can generate protective immunity in mice against RSV infection in the respiratory tract and may provide an alternative to the administration of the antibody itself.",
keywords = "Antibody, RSV, RSVAntibody{"}>Gene therapy vectors",
author = "Davor Skaricic and Chani Traube and Bishnu De and Ju Joh and Julie Boyer and Ronald Crystal and Stefan Worgall",
year = "2008",
month = "8",
day = "15",
doi = "10.1016/j.virol.2008.04.016",
language = "English",
volume = "378",
pages = "79--85",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV

AU - Skaricic, Davor

AU - Traube, Chani

AU - De, Bishnu

AU - Joh, Ju

AU - Boyer, Julie

AU - Crystal, Ronald

AU - Worgall, Stefan

PY - 2008/8/15

Y1 - 2008/8/15

N2 - Respiratory syncytial virus (RSV) is a common cause of severe lower respiratory tract infections. Protection against infection with RSV can be achieved by monthly administration of the humanized monoclonal antibody palivizumab. The present study analyzes if genetic delivery of a murine version of palivizumab by single administration would achieve high-level and sustained antibody expression to protect mice against pulmonary infection with RSV. A murine version of the palivizumab antibody was constructed by replacing the human sequences with sequences from the constant region of a murine IgG1 antibody, while preserving the complementarity-determining region. As a proof-of-principle to test the validity of the strategy, the coding sequence for the heavy and light chains were cloned into a replication-defective serotype 5 human adenovirus vector (AdαRSV). Antibody expression and specificity for RSV was confirmed by Western analysis. To determine if AdαRSV would mediate production of anti-RSV antibodies in vivo, 5 × 1010 particle units of AdαRSV or a control vector without transgene (AdNull), were administered intravenously to BALB/c mice. RSV neutralizing antibodies were detected in the serum after 4 days in mice receiving AdαRSV but not in AdNull-infected or naive mice (p < 0.05). The mice that had received AdαRSV had at least 5.4-fold lower RSV titers in the lung 4 days following intranasal challenge with RSV compared to the AdNull or naive group (p < 0.01). To evaluate long-term protection, the antibody construct was expressed in a non-human primate serotype rh.10 adeno-associated virus vector (AAVrh.10αRSV). RSV neutralizing antibodies were detected in serum and bronchoalveolar lavage fluid for up to 21 wk following intrapleural administration of AAVrh.10αRSV, but not with a control AAV vector expressing an unrelated transgene (AAVrh.10α1AT). Following challenge with RSV at 7 or 21 wk, 14.3-fold and 10.6-fold lower RSV titers were observed after 4 days in the lungs of mice that had received AAVrh.10αRSV compared to AAVrh.10α1AT (p < 0.05). Together these data demonstrate that a gene transfer strategy for delivery of an anti-RSV antibody can generate protective immunity in mice against RSV infection in the respiratory tract and may provide an alternative to the administration of the antibody itself.

AB - Respiratory syncytial virus (RSV) is a common cause of severe lower respiratory tract infections. Protection against infection with RSV can be achieved by monthly administration of the humanized monoclonal antibody palivizumab. The present study analyzes if genetic delivery of a murine version of palivizumab by single administration would achieve high-level and sustained antibody expression to protect mice against pulmonary infection with RSV. A murine version of the palivizumab antibody was constructed by replacing the human sequences with sequences from the constant region of a murine IgG1 antibody, while preserving the complementarity-determining region. As a proof-of-principle to test the validity of the strategy, the coding sequence for the heavy and light chains were cloned into a replication-defective serotype 5 human adenovirus vector (AdαRSV). Antibody expression and specificity for RSV was confirmed by Western analysis. To determine if AdαRSV would mediate production of anti-RSV antibodies in vivo, 5 × 1010 particle units of AdαRSV or a control vector without transgene (AdNull), were administered intravenously to BALB/c mice. RSV neutralizing antibodies were detected in the serum after 4 days in mice receiving AdαRSV but not in AdNull-infected or naive mice (p < 0.05). The mice that had received AdαRSV had at least 5.4-fold lower RSV titers in the lung 4 days following intranasal challenge with RSV compared to the AdNull or naive group (p < 0.01). To evaluate long-term protection, the antibody construct was expressed in a non-human primate serotype rh.10 adeno-associated virus vector (AAVrh.10αRSV). RSV neutralizing antibodies were detected in serum and bronchoalveolar lavage fluid for up to 21 wk following intrapleural administration of AAVrh.10αRSV, but not with a control AAV vector expressing an unrelated transgene (AAVrh.10α1AT). Following challenge with RSV at 7 or 21 wk, 14.3-fold and 10.6-fold lower RSV titers were observed after 4 days in the lungs of mice that had received AAVrh.10αRSV compared to AAVrh.10α1AT (p < 0.05). Together these data demonstrate that a gene transfer strategy for delivery of an anti-RSV antibody can generate protective immunity in mice against RSV infection in the respiratory tract and may provide an alternative to the administration of the antibody itself.

KW - Antibody

KW - RSV

KW - RSVAntibody">Gene therapy vectors

UR - http://www.scopus.com/inward/record.url?scp=47749126913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47749126913&partnerID=8YFLogxK

U2 - 10.1016/j.virol.2008.04.016

DO - 10.1016/j.virol.2008.04.016

M3 - Article

VL - 378

SP - 79

EP - 85

JO - Virology

JF - Virology

SN - 0042-6822

IS - 1

ER -